Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently amended) A method of promoting oligodendrocyte survival in a human suffering ~~or at risk of developing~~ from stroke ~~or another neurological disease~~ which comprises administering to said human a therapeutically effective amount of an anti-MAG antibody or a functional fragment thereof.

2. (Cancelled).

3. (Currently Amended) A method according to claim 1 ~~or use according to claim 2~~ wherein the anti-MAG antibody is an altered antibody.

4. (Currently Amended) A method according to claim 1 ~~or a use according to claim 2~~ wherein the anti-MAG antibody is a chimeric antibody.

5. (Currently Amended) A method according to claim 1 ~~or a use according to claim 2~~ wherein the anti-MAG antibody is a humanised antibody.

6. (Currently Amended) ~~Use or a~~ A method ~~according to claims 3-5~~ of promoting oligodendrocyte survival in a human suffering from stroke, which comprises administering to said human a therapeutically effective amount of an altered anti-MAG antibody or functional fragment thereof, wherein the altered antibody or functional fragment thereof binds to MAG and comprises one or more of the following complementarity determining regions (CDRs) ~~CDR's~~ .

Light chain CDRs

CDR	***According to Kabat***
L1	KSSHSVLYSSNQKNYLA
L2	WASTRES
L3	HQYLSSLT

Heavy chain CDRs

CDR	*According to Kabat*
H1	NYGMN
H2	WINTYTGEPTYADDFTG
H3	NPINYYGINYEGYVMDY

7. (Currently Amended) ~~Use or a~~ A method according to claim 6 wherein the altered antibody or functional fragment thereof comprises (a) a heavy chain variable domain which comprises one or more CDR's selected from CDRH1, CDRH2 and CDRH3 and ~~for~~ (b) a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3 .

8. (Currently Amended) ~~Use or a~~ A method according to claim 7 wherein the altered anti-MAG antibody or functional fragment thereof comprises a variable domain selected from :

a heavy chain variable domain (V_H) which comprises in sequence hypervariable regions CDRH1, CDRH2 and CDRH3

and ~~/or~~

a light chain variable domain (V_L) which comprises in sequence hypervariable regions CDRL1, CDRL2 and CDRL3.

9. (Currently Amended) ~~Use or a~~ A method according to claim 8 wherein the altered MAG antibody or functional fragment thereof comprises at least one of a heavy chain of SEQ ID NO:7, a heavy chain of SEQ ID NO:8 and ~~Sequence ID No. 7 or 8 and/or~~ a light chain of SEQ ID NO:9 ~~Sequence ID No. 9~~.

10. (Currently Amended) ~~Use or a~~ A method according to claim 8 wherein the altered anti-MAG antibody or functional fragment thereof comprises at least one of a heavy chain variable region selected from SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13, and ~~Sequence ID No. 10, 11, 12 or 13 and/or~~ a light chain variable region selected from SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16 and SEQ ID NO:17 ~~Sequence ID No. 14, 15, 16 or 17~~.

11. (Currently Amended) ~~Use or a~~ A method according to claim 10 wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region comprising SEQ ID NO:10 ~~Sequence ID No. 10~~ and a light chain variable region comprising a sequence selected from SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16 and SEQ ID NO:17 ~~Sequence ID No. 14, 15, 16 or 17~~.

12. (Currently Amended) ~~Use or a~~ A method according to claim 10 wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region comprising SEQ ID NO:11 ~~Sequence ID No. 11~~ and a light chain variable region comprising a sequence selected from SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16 and SEQ ID NO:17 ~~Sequence ID No. 14, 15, 16 or 17~~.

13. (Currently Amended) ~~Use or~~ a method according to claim 10 wherein the altered anti-MAG antibody or functional fragment thereof comprises a heavy chain variable region comprising SEQ ID NO:12 ~~Sequence ID No. 12~~ and a light chain variable region comprising a sequence selected from SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16 and SEQ ID NO:17 ~~Sequence ID No. 14, 15, 16 or 17~~.

14. (Currently Amended) ~~Use or a~~ A method according to ~~claims 10-13~~ claim 10 wherein the antibody is a humanised antibody and comprises (a) a heavy chain variable fragment comprising SEQ ID No 10, 11 or 12, (b) a constant part ~~or fragment thereof~~ of a human heavy chain or fragment thereof, (c) ~~and~~ a light chain variable fragment comprising SEQ ID No 14, 15, 16 or 17 and (d) a constant part ~~of fragment thereof~~ of a human light chain or a fragment thereof.

15. (Currently Amended) ~~Use or a~~ A method according to claim 14 wherein the humanised antibody is class IgG ~~1gG~~.

16. (Currently Amended) ~~Use or a~~ A method according to claim 15 wherein the humanised antibody is class IgG1 ~~1gG1~~.

17. (Currently Amended) ~~Use or a~~ A method according to claim~~s~~ 16 wherein the antibody heavy chain is:
MGWSCIILFLVATATGVHSQVQLVQSGSELKKPGASVKVSCKASGYTF
TNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFTGRFVFSLDT
SVSTAYLQISSLKAEDTAVYYCARNPINYYGINYEGYVMDYWGQGTLV
TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRT
PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT
LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
GK (Seq ID No 18).

18. (Currently amended) ~~Use or a~~ A method according to claim 16 wherein the antibody light chain is:
MGWSCIILFLVATATGVHSDIVMTQSPDSLAVSLGERATINCKSSHSVL
YSSNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTD
FTLTISSLQAEDVAVYYCHQYLSSLTFGQGTKLEIKRTVAAPSVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
(Seq ID No 19).

19. (Currently amended) ~~Use a~~ A method ~~according to any preceding claim~~ of promoting oligodendrocyte survival in a human suffering from stroke, which comprises administering to said human a therapeutically effective amount of an altered anti-MAG antibody or functional fragment thereof, wherein the antibody is an antibody which binds to the same epitope as the antibody having the CDR's of claim 6.